Monte Rosa Therapeutics (GLUE)
(Delayed Data from NSDQ)
$6.48 USD
+0.23 (3.68%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.49 +0.01 (0.15%) 6:48 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
Monte Rosa Therapeutics, Inc. [GLUE]
Reports for Purchase
Showing records 1 - 12 ( 12 total )
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MRT-6160 Ph 1 Initiated; Early Results Expected 1Q:25
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; MRT-2359 Update in 2H:24, MRT-6160 IND Cleared
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; MRT-2359 Update in 2H:24, MRT-6160 IND Cleared
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MRT-6160 Preclinical Data at DDW; Layering in Recent Offering
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; MRT-2359 RP2D in Q2:24, MRT-6160 Ph1 Data in Q1:25
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Stay Glued for MRT-2359 Updates Ahead
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating at OUTPERFORM and $11 PT: The QuEEN of Monte Rosa
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Monte Rosa Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Learnings From FASEB?s Ubiquitin Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
|